MedX Health Corp. Announces Executive Changes
2013年11月30日 - 6:01AM
Marketwired
MedX Health Corp. Announces Executive Changes
MISSISSAUGA, ONTARIO--(Marketwired - Nov 29, 2013) - The Board
of Directors of MedX Health Corp. ("MedX" or the "Company")
(TSX-VENTURE:MDX) is pleased to announce the following Senior
Executive changes.
Gary Van Nest will retire as Chairman, and remain as a Director
of the Company.
Steven Guillen, MBA, the current Chief Executive Officer (CEO),
and a Director, will become Chairman of the Board.
Robert von der Porten, MBA, of Toronto, a well-known and
respected Senior Operating Executive, also well experienced in
finance, corporate development, strategy, and implementation over a
broad range of industries, will become, President & Chief
Executive Officer (CEO), and a Director of the Corporation.
Louie Canitano, B.Sc, currently President and Chief Operating
Officer (COO), will continue the role of Chief Operating Officer
(COO) of the Corporation.
Jim Cooke, CPA, CA, will become Chief Financial Officer (CFO) of
the Corporation. Jim is an experienced financial executive and has
worked with large and small companies in a variety of industries,
in all phases of the corporate growth cycle.
These appointments reflect the dimensions of the business
opportunity currently facing MedX as it launches into the skin
cancer screening marketplace on a global basis and the need for
experienced operational talent at the executive level in order to
maximize the business opportunities at hand.
"MedX has a world class technology to assist in the screening
and detection of skin cancers offering significant benefits to
communities around the world in which we plan to introduce it to: I
am very excited to have the opportunity to be part of this" said
Mr. von der Porten.
These appointments, which have been approved by the Board of
Directors of MedX, are subject to all relevant regulatory and other
consents and approvals.
About MedX
MedX, headquartered in Mississauga, Ontario (Toronto), and is a
global leader in the design, manufacturing and distribution of
quality low level laser and light therapy technologies for use in
numerous medical settings, including rehab/chiropractic, dental,
wound care, and veterinary medicine, providing patients with drug
free and non-invasive treatment of tissue damage and pain. MedX
laser and light products are FDA approved, Health Canada cleared,
and CE Mark approved for use in North America as well as the
European Union. MedX Health acquired the worldwide assets of
SIMSYS™ and MoleMate™ in June, 2011. For a complete profile of MedX
and its products visit www.medxhealth.com.
About SIMSYS™ and MoleMate™ Skin Cancer Imaging
SIMSYS™ and MoleMate™ received approval from Health Canada, and
are available for all Canadian physicians and dermatologist.
SIMSYS™ and MoleMate™ is also FDA approved for use in the USA and
is currently under review for CE approval for use in Europe, the
UK, and Australia. For more information log onto:
www.simsys-molemate.com and click on 'See More', and see
approximately 2mm below the surface of suspicious moles and lesions
with additional information and images related to every mole and
lesions associated with all types of melanomas and non-melanomas.
SIMSYS™ and MoleMate™ is an optical biopsy that uses patented
technology that features a hand-held scanner device designed for
clinical office use that utilizes light to view beneath suspicious
moles or lesions in a pain free, non-invasive manner, creating
images in real-time for physicians and dermatologist to evaluate
all types of moles or lesions within seconds, providing images that
can reveal if a mole or lesion is benign, or something more
serious, often eliminating the need for skin biopsies, resulting in
less pain, scarring, and expense. Physicians and dermatologist
interested in learning more should contact MedX Health Corp. or log
onto www.simsys-molemate.com.
This press release may contain forward-looking statements,
including statements regarding the business and anticipated
financial performance of MedX Health Corp., which involve risks and
uncertainties. These risks and uncertainties may cause MedX's
actual results to differ materially from those contemplated by the
forward-looking statements. No stock exchange, securities
commission or other regulatory authority has approved or
disapproved the information contained herein.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this press
release.
Investors:MedX Health Corp.Robert von der PortenPresident and
CEO905 670 4428investor@medxhealth.com
Medx Health (TSXV:MDX)
過去 株価チャート
から 5 2024 まで 6 2024
Medx Health (TSXV:MDX)
過去 株価チャート
から 6 2023 まで 6 2024